Parichehr Hassanzadeh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1180196/publications.pdf

Version: 2024-02-01

42 papers

899 citations

471371 17 h-index 29 g-index

42 all docs 42 docs citations

times ranked

42

1292 citing authors

#	Article	IF	CITATIONS
1	Presenting a bioactive nanotherapeutic agent for colon cancer treatment. European Journal of Pharmacology, 2022, 927, 175084.	1.7	3
2	Coating of ferulic acid-loaded silk fibroin nanoparticles with neutrophil membranes: A promising strategy against the acute pancreatitis. Life Sciences, 2021, 270, 119128.	2.0	18
3	The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing. Life Sciences, 2021, 274, 119289.	2.0	9
4	The biomedical significance of multifunctional nanobiomaterials: The key components for site-specific delivery of therapeutics. Life Sciences, 2021, 277, 119400.	2.0	7
5	The capabilities of nanoelectronic 2-D materials for bio-inspired computing and drug delivery indicate their significance in modern drug design. Life Sciences, 2021, 279, 119272.	2.0	11
6	Development of a novel nanoformulation against the colorectal cancer. Life Sciences, 2021, 281, 119772.	2.0	6
7	Towards the quantum-enabled technologies for development of drugs or delivery systems. Journal of Controlled Release, 2020, 324, 260-279.	4.8	17
8	Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. Journal of Controlled Release, 2020, 328, 112-126.	4.8	35
9	The significance of artificial intelligence in drug delivery system design. Advanced Drug Delivery Reviews, 2019, 151-152, 169-190.	6.6	140
10	Tissue engineering: Still facing a long way ahead. Journal of Controlled Release, 2018, 279, 181-197.	4.8	34
11	Ignoring the modeling approaches: Towards the shadowy paths in nanomedicine. Journal of Controlled Release, 2018, 280, 58-75.	4.8	28
12	Linkers: The key elements for the creation of efficient nanotherapeutics. Journal of Controlled Release, 2018, 270, 260-267.	4.8	24
13	Ferulic acid-loaded nanostructured lipid carriers: A promising nanoformulation against the ischemic neural injuries. Life Sciences, 2018, 193, 64-76.	2.0	56
14	Nanoencapsulation: A Promising Strategy for Biomedical Applications of Ferulic Acid. Biomedical Reviews, 2018, 28, 22.	0.6	5
15	Application of carbon nanotubes as the carriers of the cannabinoid, 2-arachidonoylglycerol: Towards a novel treatment strategy in colitis. Life Sciences, 2017, 179, 66-72.	2.0	34
16	Application of modelling and nanotechnology-based approaches: The emergence of breakthroughs in theranostics of central nervous system disorders. Life Sciences, 2017, 182, 93-103.	2.0	28
17	Nerve growth factor-carbon nanotube complex exerts prolonged protective effects in an in vitro model of ischemic stroke. Life Sciences, 2017, 179, 15-22.	2.0	41
18	Ferulic acid exhibits antiepileptogenic effect and prevents oxidative stress and cognitive impairment in the kindling model of epilepsy. Life Sciences, 2017, 179, 9-14.	2.0	49

#	Article	IF	Citations
19	Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway. DARU, Journal of Pharmaceutical Sciences, 2017, 25, 25.	0.9	29
20	Application of Carbon Nanotubes for Controlled Release of Growth Factors or Endocannabinoids: A Breakthrough in Biomedicine. Biomedical Reviews, 2017, 27, 41.	0.6	12
21	Creation of Nanorobots: Both State-of-the-Science and State-of-the-Art. Biomedical Reviews, 2017, 27, 19.	0.6	11
22	The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders. Psychopharmacology, 2016, 233, 1087-1096.	1.5	20
23	Resveratrol: More than a phytochemical. Biomedical Reviews, 2016, 26, 13.	0.6	5
24	Nanopharmaceuticals: Innovative theranostics for the neurological disorders. Biomedical Reviews, 2015, 25, 25.	0.6	17
25	The endocannabinoid system: critical for the neurotrophic action of psychotropic drugs. Biomedical Reviews, 2014, 21, 31.	0.6	7
26	Tissue engineering and growth factors: updated evidence. Biomedical Reviews, 2014, 23, 19.	0.6	11
27	Computational modelling: moonlighting on the neuroscience and medicine. Biomedical Reviews, 2014, 24, 25.	0.6	12
28	Discovery of the Endocannabinoid System: A Breakthrough in Neuroscience. Archives of Neuroscience, 2014, 1 , .	0.1	1
29	The ameliorative effects of sesamol against seizures, cognitive impairment and oxidative stress in the experimental model of epilepsy. Iranian Journal of Basic Medical Sciences, 2014, 17, 100-7.	1.0	22
30	CB1 cannabinoid receptors are involved in neuroleptic-induced enhancement of brain neurotensin. Iranian Journal of Basic Medical Sciences, 2014, 17, 181-8.	1.0	3
31	Implication of NGF and endocannabinoid signaling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential. Psychopharmacology, 2013, 229, 571-578.	1.5	13
32	The CB1 Receptor-Mediated Endocannabinoid Signaling and NGF: The Novel Targets of Curcumin. Neurochemical Research, 2012, 37, 1112-1120.	1.6	29
33	Cannabinoid CB1 Receptors Mediate the Gastroprotective Effect of Neurotensin. Iranian Journal of Basic Medical Sciences, 2012, 15, 803-10.	1.0	29
34	The Effects of Progesterone on Glial Cell Line-derived Neurotrophic Factor Secretion from C6 Glioma Cells. Iranian Journal of Basic Medical Sciences, 2012, 15, 1046-52.	1.0	5
35	Involvement of the neurotrophin and cannabinoid systems in the mechanisms of action of neurokinin receptor antagonists. European Neuropsychopharmacology, 2011, 21, 905-917.	0.3	15
36	The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology, 2011, 215, 129-141.	1.5	30

#	Article	IF	CITATIONS
37	The Role of the Endocannabinoids in Suppression of the Hypothalamic-pituitary-adrenal Axis Activity by Doxepin. Iranian Journal of Basic Medical Sciences, 2011, 14, 414-21.	1.0	6
38	Cancer nanotechnology. Gastroenterology and Hepatology From Bed To Bench, 2011, 4, 63-9.	0.6	10
39	Colorectal cancer and NF-κB signaling pathway. Gastroenterology and Hepatology From Bed To Bench, 2011, 4, 127-32.	0.6	48
40	A quick look at obesity; the enemy within. Gastroenterology and Hepatology From Bed To Bench, 2011, 4, 186-91.	0.6	1
41	Nitric oxide and c-Jun N-terminal kinase are involved in the development of dark neurons induced by inflammatory pain. Synapse, 2006, 59, 101-106.	0.6	17
42	Lipid-Based Nanocarriers Provide Prolonged Anticancer Activity for Palbociclib: In Vitro and in Vivo Evaluations. Acta Medica Iranica, 0, , .	0.8	1